Vizimpro 15 mg/1

Vizimpro 15 mg is a medication used to treat certain types of cancer. This oral tablet contains dacomitinib, a targeted therapy designed to inhibit specific proteins involved in cancer cell growth.

Vizimpro 15 mg is primarily used in the treatment of non-small cell lung cancer (NSCLC). It works by targeting and inhibiting the epidermal growth factor receptor (EGFR), which can help slow the growth and spread of cancer cells. This medication is often prescribed for patients with specific genetic mutations that make them suitable candidates for this type of targeted therapy.

Common effects of Vizimpro 15 mg may include skin rash, diarrhea, and fatigue. Some users may also experience nausea, decreased appetite, and mouth sores. These effects can vary in severity and may require monitoring by a healthcare professional.

Vizimpro 15 mg should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by your healthcare provider. This medication may interact with other drugs, so it is essential to inform your healthcare provider about all medications you are taking.

Vizimpro 15 mg may interact with certain medications, including those that affect liver enzymes. It is important to avoid grapefruit and grapefruit juice, as they can increase the levels of dacomitinib in the body. Always consult your healthcare provider before starting or stopping any medication while taking Vizimpro.